Calcitonin levels in autoimmune atrophic gastritis-related hypergastrinemia.

Autoimmune atrophic gastritis Calcitonin Gastrin Hypergastrinemia

Journal

Journal of endocrinological investigation
ISSN: 1720-8386
Titre abrégé: J Endocrinol Invest
Pays: Italy
ID NLM: 7806594

Informations de publication

Date de publication:
17 Jul 2023
Historique:
received: 28 02 2023
accepted: 02 07 2023
medline: 18 7 2023
pubmed: 18 7 2023
entrez: 17 7 2023
Statut: aheadofprint

Résumé

Calcitonin (Ct) is currently the most sensitive biochemical marker of C-cell disease (medullary thyroid cancer [MTC] and C-cell hyperplasia), but its specificity is relatively low. Our aim was to examine whether autoimmune atrophic gastritis (AAG) and chronic hypergastrinemia, with or without chronic autoimmune thyroiditis (AT), are conditions associated with increased Ct levels. Three groups of patients were consecutively enrolled in this  multicentric study: group A consisted of patients with histologically-proven AAG (n = 13; 2 males, 11 females); group B fulfilled the criteria for group A but also had AT (n = 92; 15 males, 77 females); and group C included patients with AT and without AAG (n = 37; 6 males, 31 females). Median Ct levels did not differ between the three groups. Ct levels were undetectable in: 8/13 cases (61.5%) in group A, 70/92 (76.1%) in group B, and 27/37 (73.0%) in group C. They were detectable but ≤ 10 ng/L in 4/13 (30.8%), 20/92 (21.7%) and 7/37 (18.9%) cases, respectively; and they were > 10 ng/L in 1/13 (7.7%), 2/92 (2.2%) and 3/37 (8.1%) cases, respectively (P = 0.5). Only three patients had high Ct levels (> 10 ng/L) and high gastrin levels and had an MTC. There was no correlation between Ct and gastrin levels (P = 0.353, r = 0.0785). High gastrin levels in patients with AAG do not explain any hypercalcitoninemia, regardless of whether patients have AT or not. This makes it mandatory to complete the diagnostic process to rule out MTC in patients with high Ct levels and AAG.

Identifiants

pubmed: 37460914
doi: 10.1007/s40618-023-02152-x
pii: 10.1007/s40618-023-02152-x
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2023. The Author(s), under exclusive licence to Italian Society of Endocrinology (SIE).

Références

Verbeek HHG, de Groot JWB, Sluiter WJ et al (2020) Calcitonin testing for detection of medullary thyroid cancer in people with thyroid nodules. Cochrane Database of Syst Rev. https://doi.org/10.1002/14651858.CD010159.pub2
doi: 10.1002/14651858.CD010159.pub2
Censi S, Cavedon E, Fernando SW et al (2016) Calcitonin measurement and immunoassay interference: a case report and literature review. Clin Chem Lab Med 1(54):1861–1870. https://doi.org/10.1515/cclm-2015-1161
doi: 10.1515/cclm-2015-1161
Wells SA, Asa SL, Dralle H et al (2015) Revised American thyroid association guidelines for the management of medullary thyroid carcinoma. Thyroid 25:567–610. https://doi.org/10.1089/thy.2014.0335
doi: 10.1089/thy.2014.0335 pubmed: 25810047 pmcid: 4490627
Rosario PW, Calsolari MR (2013) Influence of chronic autoimmune thyroiditis and papillary thyroid cancer on serum calcitonin levels. Thyroid 23:671–674. https://doi.org/10.1089/THY.2012.0564
doi: 10.1089/THY.2012.0564 pubmed: 23327335
Maino F, Dalmiglio C, Benenati N et al (2021) Calcitonin levels in thyroid disease are not affected by autoimmune thyroiditis or differentiated thyroid carcinoma. Eur Thyroid J 10:295–305. https://doi.org/10.1159/000511080
doi: 10.1159/000511080 pubmed: 34395301
Grani G, Nesca A, del Sordo M et al (2012) Interpretation of serum calcitonin in patients with chronic autoimmune thyroiditis. Endocr Relat Cancer 19:345–349. https://doi.org/10.1530/ERC-12-0013
doi: 10.1530/ERC-12-0013 pubmed: 22399011
Wells SA, Baylin SB, Linehan WM et al (1978) Provocative agents and the diagnosis of medullary carcinoma of the thyroid gland. Ann Surg 188:139–141. https://doi.org/10.1097/00000658-197808000-00002
doi: 10.1097/00000658-197808000-00002 pubmed: 686877 pmcid: 1396745
Dockray GJ, Varro A, Dimaline R, Wang T (2001) The gastrins: their production and biological activities. Annu Rev Physiol 63:119–139. https://doi.org/10.1146/annurev.physiol.63.1.119
doi: 10.1146/annurev.physiol.63.1.119 pubmed: 11181951
Heynen G, Brassine A, Daubresse JC et al (1981) Lack of clinical and physiological relationship between gastrin and calcitonin in man. Eur J Clin Invest 11:331–335. https://doi.org/10.1111/J.1365-2362.1981.TB02125.X
doi: 10.1111/J.1365-2362.1981.TB02125.X pubmed: 6795050
Biancotti R, Dal Pozzo CA, Parente P et al (2022) The histopathological landscape of precursor lesions of gastro-entero-pancreatic neuroendocrine neoplasms. Dig Dis 41:34–48. https://doi.org/10.1159/000525421
doi: 10.1159/000525421 pubmed: 35816999
Rodriguez-Castro KI, Franceschi M, Miraglia C et al (2018) Autoimmune diseases in autoimmune atrophic gastritis. Acta Biomed 89:100–103. https://doi.org/10.23750/ABM.V89I8-S.7919
doi: 10.23750/ABM.V89I8-S.7919 pubmed: 30561426
Cellini M, Santaguida MG, Virili C et al (2017) Hashimoto’s thyroiditis and autoimmune gastritis. Front Endocrinol 8:92. https://doi.org/10.3389/FENDO.2017.00092
doi: 10.3389/FENDO.2017.00092
Rugge M, Meggio A, Pennelli G et al (2007) Gastritis staging in clinical practice: the OLGA staging system. Gut 56:631–636. https://doi.org/10.1136/GUT.2006.106666
doi: 10.1136/GUT.2006.106666 pubmed: 17142647
Pennelli G, Grillo F, Galuppini F et al (2020) Gastritis: update on etiological features and histological practical approach. Pathologica 112:153–165. https://doi.org/10.32074/1591-951X-163
doi: 10.32074/1591-951X-163 pubmed: 33179619 pmcid: 7931571
Gharib H, Papini E, Garber JR et al (2016) American association of clinical endocrinologists, american college of endocrinology, and associazione medici endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules-2016 update. Endocr Pract 22(5):622–639. https://doi.org/10.4158/EP161208.GL
doi: 10.4158/EP161208.GL pubmed: 27167915
d’Herbomez M, Caron P, Bauters C et al (2007) Reference range of serum calcitonin levels in humans: influence of calcitonin assays, sex, age, and cigarette smoking. Eur J Endocrinol 157:749–755. https://doi.org/10.1530/EJE-07-0566
doi: 10.1530/EJE-07-0566 pubmed: 18057382
Costante G, Durante C, Francis Z et al (2009) Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls. Nat Clin Pract Endocrinol Metab 5:35–44. https://doi.org/10.1038/NCPENDMET1023
doi: 10.1038/NCPENDMET1023 pubmed: 19079272
Trimboli P, Giovanella L, Crescenzi A et al (2014) Medullary thyroid cancer diagnosis: an appraisal. Head Neck 36:1216–1223. https://doi.org/10.1002/HED.23449
doi: 10.1002/HED.23449 pubmed: 23955938
Kloos RT, Eng C, Evans DB et al (2009) Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19:565–612. https://doi.org/10.1089/THY.2008.0403
doi: 10.1089/THY.2008.0403 pubmed: 19469690
Trimboli P, Seregni E, Treglia G et al (2015) Procalcitonin for detecting medullary thyroid carcinoma: a systematic review. Endocr Relat Cancer 22:R157–R164. https://doi.org/10.1530/ERC-15-0156
doi: 10.1530/ERC-15-0156 pubmed: 25934688
Toledo SPA, Lourenço DM, Santos MA et al (2009) Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma. Clinics 64:699–706. https://doi.org/10.1590/S1807-59322009000700015
doi: 10.1590/S1807-59322009000700015 pubmed: 19606248 pmcid: 2710445
Giannetta E, Guarnotta V, Altieri B et al (2020) Endocrine tumours: calcitonin in thyroid and extra-thyroid neuroendocrine neoplasms: the two-faced Janus. Eur J Endocrinol 183:R197–R215. https://doi.org/10.1530/EJE-20-0506
doi: 10.1530/EJE-20-0506 pubmed: 33112280
Franchimont P, Heynen G (1976) Parathormone and calcitonin radioimmunoassay in various medical and osteoarticular disorders. J Nuclear Med Book Reviews, Philadelphia, Lippincott, pp 134
Erdogan MF, Gursoy A, Kulaksizoglu M (2006) Long-term effects of elevated gastrin levels on calcitonin secretion. J Endocrinol Invest 29:771–775. https://doi.org/10.1007/BF03347369
doi: 10.1007/BF03347369 pubmed: 17114906
Becker KL, Silva OL, Cyrus J et al (1980) Hypercalcitonemia in pernicious anemia. Experientia 36:1330–1331. https://doi.org/10.1007/BF01969618
doi: 10.1007/BF01969618 pubmed: 7449924
Brandsborg M, Nielsen HE, Brandsborg O et al (1980) The role of serum gastrin in the secretion of calcitonin: studies in patients with pernicious anaemia and in healthy subjects. Scand J Gastroenterol 15:23–28. https://doi.org/10.3109/00365528009181426
doi: 10.3109/00365528009181426 pubmed: 7367817
Fahrenkrug J, De de Muckadell OB, Rehfeld JF (1977) Serum calcitonin in hypergastrinaemia due to achlorhydria. Acta Endocrinol 86:140–145. https://doi.org/10.1530/ACTA.0.0860140
doi: 10.1530/ACTA.0.0860140
Lamers CBH, Hackeng WHL, Thien T, Van Tongeren JHM (1980) Serum concentrations of immunoreactive calcitonin in patients with hypergastrinaemia. Digestion 20:379–382. https://doi.org/10.1159/000198477
doi: 10.1159/000198477 pubmed: 6105986
Rehfeld JF (2008) The art of measuring gastrin in plasma: a dwindling diagnostic discipline? Scand J Clin Lab Invest 68:353–361. https://doi.org/10.1080/00365510701771831
doi: 10.1080/00365510701771831 pubmed: 19172694
Said SI, Zfass AM (1978) Gastrointestinal hormones. Dis Mon 24:1–40. https://doi.org/10.1016/S0011-5029(78)80007-8
doi: 10.1016/S0011-5029(78)80007-8 pubmed: 95663
Karanikas G, Moameni A, Poetzi C et al (2004) Frequency and relevance of elevated calcitonin levels in patients with neoplastic and nonneoplastic thyroid disease and in healthy subjects. J Clin Endocrinol Metab 89:515–519. https://doi.org/10.1210/jc.2003-030709
doi: 10.1210/jc.2003-030709 pubmed: 14764755
Libbey NP, Nowakowski KJ, Tucci JR (1989) C-cell hyperplasia of the thyroid in a patient with goitrous hypothyroidism and Hashimoto’s thyroiditis. Am J Surg Pathol 13:71–77. https://doi.org/10.1097/00000478-198901000-00011
doi: 10.1097/00000478-198901000-00011 pubmed: 2909199
Guyetant S, Wion-Barbot N, Rousselet MC et al (1994) C-cell hyperplasia associated with chronic lymphocytic thyroiditis: a retrospective quantitative study of 112 cases. Hum Pathol 25:514–521. https://doi.org/10.1016/0046-8177(94)90124-4
doi: 10.1016/0046-8177(94)90124-4 pubmed: 8200646
Lima MA, Santos BM, Borges MF (1998) Quantitative analysis of C cells in Hashimoto’s thyroiditis. Thyroid 8:505–509. https://doi.org/10.1089/THY.1998.8.505
doi: 10.1089/THY.1998.8.505 pubmed: 9669288
Poppe K, Verbruggen LA, Velkeniers B et al (1999) Calcitonin reserve in different stages of atrophic autoimmune thyroiditis. Thyroid 9:1211–1214. https://doi.org/10.1089/THY.1999.9.1211
doi: 10.1089/THY.1999.9.1211 pubmed: 10646660
Borges MF, Abelin NMA, Menezes FOM et al (1998) Calcitonin deficiency in early stages of chronic autoimmune thyroiditis. Clin Endocrinol (Oxf) 49:69–75. https://doi.org/10.1046/J.1365-2265.1998.00478.X
doi: 10.1046/J.1365-2265.1998.00478.X pubmed: 9797849
Body JJ, Demeester-Mirkine N, Borkowski A et al (1986) Calcitonin deficiency in primary hypothyroidism. J Clin Endocrinol Metab 62:700–703. https://doi.org/10.1210/JCEM-62-4-700
doi: 10.1210/JCEM-62-4-700 pubmed: 3949951

Auteurs

S Censi (S)

Department of Medicine (DIMED), Endocrinology Unit, University of Padua, Padua, Italy.

S Carducci (S)

Department of Medicine (DIMED), Endocrinology Unit, University of Padua, Padua, Italy.

G Zoppini (G)

Endocrinologia, Diabetologia E Malattie del Metabolismo, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.

A Toffalini (A)

Endocrinologia, Diabetologia E Malattie del Metabolismo, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.

V Tonelli (V)

Endocrinologia, Diabetologia E Malattie del Metabolismo, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.

J Manso (J)

Department of Medicine (DIMED), Endocrinology Unit, University of Padua, Padua, Italy.
Department of Woman's and Child 's Health-Pediatric Endocrinology and Adolescence Unit, University Hospital of Padua, Padua, Italy.

C Sabbadin (C)

Department of Medicine (DIMED), Endocrinology Unit, University of Padua, Padua, Italy.

F Galuppini (F)

Department of Medicine (DIMED), Surgical Pathology & Cytopathology Unit, University of Padua, Padua, Italy.

G Pennelli (G)

Department of Medicine (DIMED), Surgical Pathology & Cytopathology Unit, University of Padua, Padua, Italy.

I Piva (I)

Department of Medicine (DIMED), Endocrinology Unit, University of Padua, Padua, Italy.

S Barollo (S)

Department of Medicine (DIMED), Endocrinology Unit, University of Padua, Padua, Italy.

L Bertazza (L)

Department of Medicine (DIMED), Endocrinology Unit, University of Padua, Padua, Italy.

V Pilotto (V)

Gastroenterology Unit, Department of Surgical, Oncological and Gastroenterological Sciences (DiSCOG), University of Padua, Padua, Italy.

D Basso (D)

Laboratory Medicine, Department of Medicine (DIMED), University of Padua, Padua, Italy.

B Fabris (B)

Dipartimento Di Scienze Mediche, Chirurgiche E Della Salute, Università Degli Studi Di Trieste, Trieste, Italy.

S Bernardi (S)

Dipartimento Di Scienze Mediche, Chirurgiche E Della Salute, Università Degli Studi Di Trieste, Trieste, Italy.

F Farinati (F)

Gastroenterology Unit, Department of Surgical, Oncological and Gastroenterological Sciences (DiSCOG), University of Padua, Padua, Italy.

C Scaroni (C)

Department of Medicine (DIMED), Endocrinology Unit, University of Padua, Padua, Italy.

C Mian (C)

Department of Medicine (DIMED), Endocrinology Unit, University of Padua, Padua, Italy. caterina.mian@unipd.it.
Department of Medical and Surgical Sciences, Endocrinology Unit, Via Ospedale N.105, 35128, Padua, Italy. caterina.mian@unipd.it.

Classifications MeSH